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The human cerebrospinal uid metabolomic 
database
Cerebrospinal fluid (CSF) is considered to be an excellent 
source of molecular biomarkers of neurological function 
since it is in direct contact with the extracellular space of 
the brain. As the CSF contains metabolites and other 
molecules that can reflect altered brain function, sys-
tematic studies of the CSF metabolome can potentially 
offer new insights into central nervous system (CNS) 
disorders. ese include neurodegenerative conditions 
such as Alzheimer’s disease, Parkinson’s disease, amyo-
trophic lateral sclerosis and multiple sclerosis, and neuro-
psychiatric diseases such as schizophrenia, depression 
and bipolar disorder. At the time it was first published in 
2007, the CSF metabolome database [1] contained 308 
detectable metabolites, with information on names, struc-
tures, concentrations, literature references and disease 
associations. Since this time, the database has been 
applied to the study of numerous CNS diseases.
Technological advances expand the spectrum of 
CSF metabolites
A new study from David Wishart and co-workers, 
published in Genome Medicine, represents an important 
work in the field of biomarker discovery [2]. e authors 
describe how continuing advances in analytical tech-
nologies have led to the discovery of many new CSF 
metabolites, allowing expansion of the CSF metabolome 
database. ey applied five different metabolomic plat-
forms to characterize multiple CSF samples, and this 
resulted in identification of new constituent metabolites 
and an increase in size of the database by approximately 
50%. e authors now give an updated CSF metabolome 
database that contains detailed information of 476 
compounds. Furthermore, the authors have carried out 
an extensive literature review for additional information 
on these compounds, including their concentrations and 
disease associations. e newly identified molecules 
consist of a number of metabolites (6 acylcarnitines, 13 
amino acids, hexose, 42 phosphatidylcholines, 2 lyso-
phosphatidylcholines and 14 sphingolipids) that should 
aid neurological studies involving changes in energy 
metabolism. In addition, Wishart et al. also identified 37 
metal ions, which could be useful in studies of neuro-
degenerative diseases such as Alzheimer’s disease, since 
alterations in metal ions are known to occur in this 
condition [3].
Integrating metabolome and proteome proles 
of CSF
Despite the comprehensiveness of this updated CSF 
meta bolome database, there is still a need for continued 
developments, including integration with a CSF proteo-
mics database. e most extensive CSF proteome charac-
terized thus far contains 2,630 proteins [4]. However, 
integration of these databases will require the application 
of sophisticated bioinformatic approaches. Also, studies 
involving changes in CSF metabolites and proteins may 
require analyses using a single platform to rule out 
artifacts found as a result of cross-platform comparisons. 
is is important considering that proteins, metabolites 
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and other molecules are interactive as components of the 
same biological networks and this is manifested at 
multiple levels in a systems biology manner. For example, 
protein hormones, including insulin and VGF, regulate 
the levels of metabolites such as glucose, adreno-
corticotropic hormone regulates production and release 
of the steroid hormone cortisol, and growth factor 
proteins such as platelet-derived growth factor can affect 
the action of dopaminergic and serotonergic neuro trans-
mitters. As biomedical research evolves from traditional 
clinical and biological investigations to incorporate 
multi-omic technologies, integration of the resulting data 
has emerged as a critical next stage.
In line with this, several groups, including our own, 
have investigated both metabolic and proteomic profiles 
of CSF samples in normal and disease states. For 
example, Blanchet and colleagues [5] have shown that a 
fusion of proteome and metabolome data leads to higher 
predictive accuracy in a rat model of autoimmune 
encephalomyelitis. Interestingly, the molecular signature 
comprises transporter proteins such as hemopexin, 
serum albumin and serotransferrin, along with metabo-
lites such as succinate, pantothenate and glutamine, 
which are involved in multiple complex biological path-
ways. An alternative example comes from our own group, 
by identification of a metabolome profile comprising 
glucose, acetate, alanine and glutamine that could distin-
guish patients with schizophrenia from control patients, 
with high accuracy [6]. As a complement to this meta-
bolome study, we also profiled proteins and peptides in 
the same CSF samples [7]. e key alterations identified 
were increased levels of a VGF-derived peptide and 
decreased levels of the transport protein transthyretin. 
e two studies together provide a more complete 
picture of the changes seen in patients with schizophrenia 
as VGF is known to affect the levels of energy-related 
metabolites such as glucose, and transthyretin directly 
interacts with and is responsible for the transport of 
metabolites such as the thyroid hormone thyroxine (T4) 
and the vitamin-A-related molecule retinol.
As an extension, we are now profiling CSF from 
patients with schizophrenia and controls using multiplex 
immunoassay profiling to simultaneously measure 
multiple proteins and metabolites (Figure 1). is multi-
plex platform will allow researchers to target a broader 
combination of metabolites. As all of these proteins 
interact with small molecules to exert their functions, it 
is clear that integration of ‘omic’ platforms is required for 
a better understanding of disease processes.
Future perspectives in CSF metabolomics and 
beyond
Wishart and colleagues have made a significant contri-
bution to our ability to unravel disease processes through 
their use of multiple platforms to increase the size of the 
metabolome database [2]. However, future profiling 
studies will require incorporation of assays for proteins 
and metabolites into single platforms to identify compo-
nents that are altered in disease. is is because cross-
platform comparisons are useful for cataloguing compo-
nents but not for reliable quantitative studies. It is clear 
from the metabolome and proteome studies described 
above that small molecules and proteins are highly inter-
active in bringing about physiological effects in complex 
biological systems. erefore, a more complete under-
standing of diseases and other biological effects requires 
a massive integration of technologies and statistical 
methods. However, there is now reason for optimism 
Figure 1. An overview of the multiplex immunoassay technique for measurement of cerebrospinal uid metabolites and proteins.
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that further technological and interdisciplinary advance­
ments will overcome current limitations in the field to 
help usher biomarkers fully into the 21st century. This 
can be achieved either by integrating the analyses using a 
single platform, such as the multiplex immunoassay 
method described above, or by using sophisticated bio­
informatic and biostatistical methods to integrate the 
metabolite and proteomic data acquired using different 
platforms.
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